-
-
-
-
-
-
-
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
-
-
-
-
-
-
-
Maze Therapeutics raises $150 million in oversubscribed private placement
-
-
-
-
-
-
-
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
-
-
-
-
-
1,199,636 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

